Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer

Last updated: October 13, 2015
Sponsor: Gary Morrow
Overall Status: Completed

Phase

3

Condition

Pain (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00042848
CDR0000069477
URCC-U2901
U10CA037420
  • Ages 18-120
  • All Genders

Study Summary

RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known.

PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer.

Eligibility Criteria

Inclusion

DISEASE CHARACTERISTICS:

  • Diagnosis of cancer

  • Concurrently receiving or has previously received chemotherapy and is scheduled for at least 3 additional courses of chemotherapy

  • Each course of chemotherapy must be at least 2 weeks in duration

  • No concurrent radiotherapy or interferon therapy

  • Brief Fatigue Inventory question #3 "fatigue worst" score of 2 or greater 1 week after first chemotherapy course

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Not specified

Life expectancy

  • At least 6 months

Hematopoietic

  • Not specified

Hepatic

  • No uncontrolled anemia

Renal

  • Not specified

Cardiovascular

  • No history of clinically significant cardiac disease, including any of the following:

  • Unstable angina

  • Left ventricular hypertrophy

  • Ischemic echocardiogram changes

  • Chest pain

  • Arrhythmia

  • Other clinically significant manifestations of mitral valve prolapse in association with use of central nervous system stimulants (e.g., caffeine, amphetamines, or methylphenidate)

  • No uncontrolled hypertension

Gastrointestinal

  • Able to swallow medication

  • No narrowing (pathological or iatrogenic) or obstruction of the gastrointestinal tract

Other

  • No severe headaches

  • No glaucoma

  • No seizure disorder

  • No narcolepsy

  • No psychotic disorder

  • No Tourette's syndrome

  • No alcohol or drug abuse

  • Not pregnant or nursing

  • Fertile patients must use effective barrier contraception during and for at least 1 full menstrual cycle after study completion

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • No concurrent chronic corticosteroids

Radiotherapy

  • See Disease Characteristics

Surgery

  • Not specified

Other

  • No prior modafinil

  • At least 30 days since prior regular use of psychostimulants (e.g., amphetamines, methylphenidate, or pemoline) or monoamine oxidase inhibitors (MAOIs)

  • No concurrent alcohol

  • Concurrent acetaminophen with codeine or hydrocodone bitartrate allowed

  • Concurrent phenytoin allowed

  • Concurrent warfarin for anticoagulation and low-dose warfarin (1 mg by mouth daily) for maintenance of venous access devices allowed

Study Design

Total Participants: 837
Study Start date:
August 01, 2002
Estimated Completion Date:
October 31, 2007

Study Description

OBJECTIVES:

  • Assess the degree to which modafinil can reduce fatigue in cancer patients receiving chemotherapy.

  • Assess the relationship between depression and fatigue in patients treated with this drug.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Beginning on day 5 of the second course of chemotherapy, patients receive oral modafinil once daily.

  • Arm II: Beginning on day 5 of the second course of chemotherapy, patients receive oral placebo once daily.

Treatment in both arms continues until day 7 of course 4 of chemotherapy in the absence of disease progression or unacceptable toxicity.

Fatigue and quality of life are assessed on day 7 of courses 2-4 of chemotherapy.

PROJECTED ACCRUAL: A total of 837 patients will be accrued for this study within approximately 2.5 years.

Connect with a study center

  • MBCCOP - Gulf Coast

    Mobile, Alabama 36606
    United States

    Site Not Available

  • CCOP - Western Regional, Arizona

    Phoenix, Arizona 85006-2726
    United States

    Site Not Available

  • CCOP - Santa Rosa Memorial Hospital

    Santa Rosa, California 95403
    United States

    Site Not Available

  • Medical Center of Aurora - South Campus

    Aurora, Colorado 80012-0000
    United States

    Site Not Available

  • Boulder Community Hospital

    Boulder, Colorado 80301-9019
    United States

    Site Not Available

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado 80933
    United States

    Site Not Available

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado 80224
    United States

    Site Not Available

  • Porter Adventist Hospital

    Denver, Colorado 80210
    United States

    Site Not Available

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado 80218
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers - Denver Rose

    Denver, Colorado 80220
    United States

    Site Not Available

  • St. Joseph Hospital

    Denver, Colorado 80218-1191
    United States

    Site Not Available

  • Swedish Medical Center

    Englewood, Colorado 80112
    United States

    Site Not Available

  • Sky Ridge Medical Center

    Lone Tree, Colorado 80124
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers - Longmont

    Longmont, Colorado 80501
    United States

    Site Not Available

  • St. Mary-Corwin Regional Medical Center

    Pueblo, Colorado 81004
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers - Thornton

    Thornton, Colorado 80229
    United States

    Site Not Available

  • MBCCOP - Hawaii

    Honolulu, Hawaii 96813
    United States

    Site Not Available

  • MBCCOP - University of Illinois at Chicago

    Chicago, Illinois 60612-7323
    United States

    Site Not Available

  • CCOP - Central Illinois

    Decatur, Illinois 62526
    United States

    Site Not Available

  • CCOP - Evanston

    Evanston, Illinois 60201
    United States

    Site Not Available

  • CCOP - Wichita

    Wichita, Kansas 67214-3882
    United States

    Site Not Available

  • CCOP - Kalamazoo

    Kalamazoo, Michigan 49007-3731
    United States

    Site Not Available

  • CCOP - Metro-Minnesota

    St. Louis Park, Minnesota 55416
    United States

    Site Not Available

  • CCOP - Kansas City

    Kansas City, Missouri 64131
    United States

    Site Not Available

  • CCOP - Nevada Cancer Research Foundation

    Las Vegas, Nevada 89106
    United States

    Site Not Available

  • CCOP - Hematology-Oncology Associates of Central New York

    East Syracuse, New York 13057
    United States

    Site Not Available

  • CCOP - North Shore University Hospital

    Manhasset, New York 11030
    United States

    Site Not Available

  • CCOP - Southeast Cancer Control Consortium

    Goldsboro, North Carolina 27534-9479
    United States

    Site Not Available

  • CCOP - Columbus

    Columbus, Ohio 43215
    United States

    Site Not Available

  • CCOP - Dayton

    Dayton, Ohio 45429
    United States

    Site Not Available

  • CCOP - Columbia River Oncology Program

    Portland, Oregon 97225
    United States

    Site Not Available

  • CCOP - Greenville

    Greenville, South Carolina 29615
    United States

    Site Not Available

  • CCOP - Virginia Mason Research Center

    Seattle, Washington 98101
    United States

    Site Not Available

  • CCOP - Northwest

    Tacoma, Washington 98405-0986
    United States

    Site Not Available

  • CCOP - Marshfield Clinic Research Foundation

    Marshfield, Wisconsin 54449
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.